

THE TRENDLINES GROUP LTD.

(Incorporated in Israel)

(Company Registration No. 513970947)

Incorporation of Portfolio Companies which are considered as Subsidiaries

The board of directors (the “**Board**”) of The Trendlines Group Ltd. (the “**Company**” and together with its subsidiaries and associated companies, the “**Group**”) wishes to announce that the following portfolio companies, which are considered Subsidiaries¹, have recently been incorporated by the Group.

Name of Portfolio Company	Country of Incorporation	Principal Activity	Issued and Paid-up capital	Percentage of Ownership by Group Entity			Total Percentage of Ownership
				Trendlines Medical Singapore Pte. Ltd.	The Trendlines Group Ltd.	Trendlines Incubators Israel Ltd.	
InterVaal Pte. Ltd.	Singapore	Intervaal Pte. Ltd. is focused on developing a catheter to address the widespread problem of catheter-associated urinary tract infections (CAUTIs).	US\$97,416	49%	-	49%	98%
Continale Medical Pte. Ltd.	Singapore	Continale Medical Pte. Ltd. is focused on developing a	S\$1	36.1%	63.9%	-	100%

¹ As such term is defined under the Companies Act (Chapter 50) of Singapore.

		device to alleviate stress urinary incontinence (SUI).					
Avir Medical Pte. Ltd.	Singapore	Avir Medical Pte. Ltd. is focused on developing a novel endotracheal tube to reduce ventilator-associated pneumonia.	S\$1	49%	36%	-	85%
Medulla Pro Technology Pte. Ltd.	Singapore	Medulla Pro Technology Pte. Ltd. is focused on developing an ultrasound-guided imaging system for lumbar puncture.	S\$1	60%	40%	-	100%
Ayzer Sense Pte. Ltd.	Singapore	Ayzer Sense Pte. Ltd. is focused on developing a low-cost, Smart Automated Body-Pressure Redistributor (SABPR) to prevent the development of pressure ulcers (pressure sores).	S\$52,979.04	70%	-	-	70%
EndoSiQ Technology Pte. Ltd.	Singapore	EndoSiQ Pte. Ltd. is focused on developing a proprietary software application to analyse real-time visual images of the bladder. The software will help pinpoint unusual muscle group activities for timely intervention, which will help in the treatment of overactive bladder (OAB).	S\$1	65%	35%	-	100%

The incorporation of the above-mentioned subsidiaries did not have any material impact on the net tangible assets and earnings per share of the Group for the financial year ended 31 December 2018.

None of the Company's Directors, substantial shareholders and/or any of their respective associates has any interest, direct or indirect (other than through their shareholdings in the Company, if any), in the above-mentioned portfolio companies.

**BY ORDER OF THE BOARD
THE TRENDLINES GROUP LTD.**

Haim Brosh,
Joint Company Secretary

24 January 2019

This announcement has been prepared by The Trendlines Group Ltd. (the "Company") and its contents have been reviewed by PrimePartners Corporate Finance Pte. Ltd. (the "Sponsor") for compliance with the Singapore Exchange Securities Trading Limited (the "SGX-ST") Listing Manual Section B: Rules of Catalyst. The Sponsor has not verified the contents of this announcement.

This announcement has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this announcement, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Ms Jennifer Tan, Senior Manager, Continuing Sponsorship (Mailing Address: 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318 and E-mail: sponsorship@ppcf.com.sg).